MX385085B - Uso de beta-agonistas del receptor de la hormona tiroidea. - Google Patents

Uso de beta-agonistas del receptor de la hormona tiroidea.

Info

Publication number
MX385085B
MX385085B MX2018012900A MX2018012900A MX385085B MX 385085 B MX385085 B MX 385085B MX 2018012900 A MX2018012900 A MX 2018012900A MX 2018012900 A MX2018012900 A MX 2018012900A MX 385085 B MX385085 B MX 385085B
Authority
MX
Mexico
Prior art keywords
agonists
hormone receptor
thyroid hormone
receptor beta
beta
Prior art date
Application number
MX2018012900A
Other languages
English (en)
Other versions
MX2018012900A (es
Inventor
Brian Lian
Hongjian Jiang
Mark Erion
Misha Dinerman
Rochelle Hanley
Serge Boyer
Original Assignee
Viking Therapeutics Inc
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viking Therapeutics Inc, Metabasis Therapeutics Inc filed Critical Viking Therapeutics Inc
Publication of MX2018012900A publication Critical patent/MX2018012900A/es
Publication of MX385085B publication Critical patent/MX385085B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos útiles para tratar la adrenoleucodistrofia enlazada a X.
MX2018012900A 2016-04-22 2017-04-24 Uso de beta-agonistas del receptor de la hormona tiroidea. MX385085B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662326436P 2016-04-22 2016-04-22
PCT/US2017/029120 WO2017185087A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (2)

Publication Number Publication Date
MX2018012900A MX2018012900A (es) 2019-07-01
MX385085B true MX385085B (es) 2025-03-14

Family

ID=60116400

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012900A MX385085B (es) 2016-04-22 2017-04-24 Uso de beta-agonistas del receptor de la hormona tiroidea.

Country Status (10)

Country Link
US (3) US11351183B2 (es)
EP (1) EP3445373B1 (es)
JP (1) JP6931042B2 (es)
KR (1) KR102407059B1 (es)
AU (1) AU2017252126B2 (es)
BR (1) BR112018071586A2 (es)
CA (1) CA3021681C (es)
ES (1) ES2992773T3 (es)
MX (1) MX385085B (es)
WO (1) WO2017185087A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992773T3 (en) 2016-04-22 2024-12-18 Viking Therapeutics Inc Use of thyroid beta-agonists
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
JP2007524656A (ja) 2003-10-23 2007-08-30 セルジーン・コーポレーション 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法
AU2006249350B2 (en) 2003-11-19 2012-02-16 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
CN102240278A (zh) 2004-12-08 2011-11-16 矫正诊疗公司 治疗与视黄醇有关的疾病的方法、分析和组合物
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
WO2007097289A1 (ja) 2006-02-20 2007-08-30 Takeda Pharmaceutical Company Limited 新規医薬
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
RU2631805C2 (ru) 2011-06-21 2017-09-26 Элнилэм Фармасьютикалз, Инк. Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
WO2016134292A1 (en) 2015-02-20 2016-08-25 Oregon Health & Science University Derivatives of sobetirome
KR102757616B1 (ko) 2016-02-29 2025-01-21 필립모리스 프로덕츠 에스.에이. 힌지 리드 용기 및 블랭크
ES2992773T3 (en) 2016-04-22 2024-12-18 Viking Therapeutics Inc Use of thyroid beta-agonists
CN109641003A (zh) 2016-04-22 2019-04-16 维京治疗股份有限公司 甲状腺β-激动剂的应用
JP6982004B2 (ja) 2016-05-18 2021-12-17 オレゴン ヘルス アンド サイエンス ユニバーシティ ソベチロム誘導体

Also Published As

Publication number Publication date
CA3021681C (en) 2024-09-24
MX2018012900A (es) 2019-07-01
US20190321379A1 (en) 2019-10-24
KR102407059B1 (ko) 2022-06-10
JP6931042B2 (ja) 2021-09-01
US11351183B2 (en) 2022-06-07
KR20190039027A (ko) 2019-04-10
AU2017252126A1 (en) 2018-11-08
BR112018071586A2 (pt) 2019-02-12
US12440502B2 (en) 2025-10-14
US20220257618A1 (en) 2022-08-18
WO2017185087A1 (en) 2017-10-26
EP3445373A4 (en) 2019-12-18
AU2017252126B2 (en) 2023-02-09
US20250000880A1 (en) 2025-01-02
JP2019515033A (ja) 2019-06-06
EP3445373B1 (en) 2024-08-21
US11951114B2 (en) 2024-04-09
ES2992773T3 (en) 2024-12-18
EP3445373A1 (en) 2019-02-27
CA3021681A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
DOP2017000110A (es) Receptores quimericos de antígeno anti–cldn y métodos de uso
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
CR20180594A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CL2017000654A1 (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
MY195115A (en) Antibodies targeting g-protein coupled receptor and methods of use
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
LT3183268T (lt) Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
ES2796903T8 (es) Procedimiento de uso de inmunoconjugados anti-CD79b
CO2017002159A2 (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
MX384989B (es) Uso de un agonista del receptor x retinoide (rxr) en combinación con una hormona tiroidea para el tratamiento de esclerosis múltiple.
CL2016002008A1 (es) Proceso para la elaboración de derivados de pirimidin sulfamida.
CL2018003045A1 (es) Semaglutida en afecciones cardiovasculares.
MX385085B (es) Uso de beta-agonistas del receptor de la hormona tiroidea.
EA201790373A1 (ru) Способы получения модуляторов toll-подобных рецепторов
MX2018012904A (es) Uso de beta-agonistas del receptor de la hormona tiroidea.
MX384037B (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.